Fig. 2

Neuropathological characterization of the cohort used for the RNA sequencing and immunohistochemical experiments. 35 samples were included and categorized based on the amount of AD neuropathology and cognition. A Examples of section of the SFG of donors with intermediate to high amount of pTau (AT8) and beta amyloid (4G8) pathology that were included in the AD (left panels) and resilient group (right panels). B Neuropathological scores of the different groups with amyloid pathology on the x-axis (Thal and CERAD according to the ABC score from the National Institute on Aging-Alzheimer’s Association guidelines) and tau pathology (Braak stage). C The plaque load was significantly higher in both resilient and AD compared to control (Kruskall–Wallis; H = 25.63, p < 0.0001, AD vs control; p =  < 0.0001, resilient vs control; p = 0.005, resilient vs. AD; p = 0.252). D Quantification of the pTau load, showing significantly more pTau in the resilient and AD groups (Fig. 2D: Kruskal–Wallis H = 23.08, p < 0.0001, AD vs control; p =  < 0.0001, resilient vs control; p = 0.037, resilient vs AD; p = 0.085). Of note, there is a trend of increased pTau pathology in the AD group compared to the resilient group. Scale bars in panel A indicate 1 mm in upper panel and 50 µm in lower panel. p < 0.05: *, p < 0.01: **, p < 0.001: ***. ns = not significant